Welcome to our dedicated page for TC BioPharm (Holdings) news (Ticker: TCBPY), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) stock.
TC BioPharm (Holdings) PLC (TCBPY) is described as a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies for cancer and other indications. News about the company often centers on developments in its gamma-delta T cell platform, clinical trial progress, intellectual property, and material corporate events affecting its securities.
One notable category of news involves clinical and scientific updates. The company has highlighted human efficacy data in acute myeloid leukemia and has reported investigator-initiated clinical trials, including a Phase 2b/3 pivotal trial using its proprietary CryoTC allogeneic technology. Coverage may include progress reports, trial design updates, or other disclosures related to its unmodified gamma-delta T cell product line.
Another important news theme is intellectual property. TC BioPharm has announced the grant of a European Patent Office patent for targeting microbial, oncological, and viral indications using modified gamma-delta T cells. Related news can describe how this patent fits into the company’s stated commercial strategy and its efforts to refine targeting of modified cell therapies.
Regulatory and corporate events are also prominent in TC BioPharm news. SEC filings and company announcements have described the appointment of administrators to a subsidiary, the appointment of interim liquidators to TC BioPharm (Holdings) PLC, and the decision to deregister its American Depositary Shares by filing Form 15. These items are material for understanding the status of TCBPY as a security and the company’s corporate trajectory.
Investors and observers who follow TCBPY-related news can use this page to review updates on clinical activities, patents, and significant corporate and regulatory steps disclosed in official communications and filings.
TC BioPharm (OTC: TCBPY) has secured a significant patent from the European Patent Office for its modified gamma delta T cell therapies targeting microbial, oncological, and viral indications. The patent strengthens the company's intellectual property portfolio in the development of allogeneic cell therapies.
According to CEO Bryan Kobel, this patent advancement is particularly important as it addresses the challenge of off-target recognition in modified cell therapies, potentially enabling broader therapeutic applications while reducing toxicity risks. The company plans to proceed with the patent process in specific European countries in line with its commercial strategy.